Polycyclic antagonists of lysophosphatidic acid receptors

A method of treating lung fibrosis, renal fibrosis, liver fibrosis, or melanoma, in a mammal comprising administering to said mammal a therapeutically effective amount of a compound according to the following Formula (I), or a pharmaceutically acceptable salt thereof:

• wherein,
• R1 is —CO2H, —CO2RD, —CN, —C(═O)N(R9)2, —C(═O)NHCH2CH2SO3H, —C(═O)NHSO2R10, tetrazolyl, or 5-oxo-2,5-dihydro-[1,2,4]oxadiazol-3-yl;
• RD is H or C1-C4alkyl;
• R3 is H, C1-C4alkyl, C3-C6cycloalkyl, or C1-C4fluoroalkyl;
• R4 is —NR7C(═O)OCH(R8)—CY;
• R7 is H or C1-C4alkyl;
• R8 is H, C1-C4alkyl, or C1-C4fluoroalkyl;
• CY is a substituted or unsubstituted C3-C6cycloalkyl or a substituted or unsubstituted phenyl, wherein if CY is substituted then CY is substituted with 1 or 2 RC;
• R9 is H, C1-C6alkyl, C1-C6-fluoroalkyl, C3-C6cycloalkyl, or a substituted or unsubstituted phenyl;
• R10 is a C1-C6alkyl, C1-C6-fluoroalkyl, C3-C6cycloalkyl, or a substituted or unsubstituted phenyl;
• each of RA, RB, and RC are independently selected from F, Cl, Br, I, —CN, —OH, C1-C4alkyl, C1-C4fluoroalkyl, C1-C4fluoroalkoxy, C1-C4alkoxy, and C1-C4heteroalkyl;
• m is 0, 1, or 2;
• n is 1, 2, 3 or 4;
• and
• p is 0, 1, or 2;
• in combination with at least one additional agent selected from the group consisting of an immunosuppressant, an anti-inflammatory agent, and an agent used in the treatment of a respiratory condition.